These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
237 related articles for article (PubMed ID: 23760517)
1. Towards a vaccine to prevent cancer in Lynch syndrome patients. von Knebel Doeberitz M; Kloor M Fam Cancer; 2013 Jun; 12(2):307-12. PubMed ID: 23760517 [TBL] [Abstract][Full Text] [Related]
2. Recurrent Frameshift Neoantigen Vaccine Elicits Protective Immunity With Reduced Tumor Burden and Improved Overall Survival in a Lynch Syndrome Mouse Model. Gebert J; Gelincik O; Oezcan-Wahlbrink M; Marshall JD; Hernandez-Sanchez A; Urban K; Long M; Cortes E; Tosti E; Katzenmaier EM; Song Y; Elsaadi A; Deng N; Vilar E; Fuchs V; Nelius N; Yuan YP; Ahadova A; Sei S; Shoemaker RH; Umar A; Wei L; Liu S; Bork P; Edelmann W; von Knebel Doeberitz M; Lipkin SM; Kloor M Gastroenterology; 2021 Oct; 161(4):1288-1302.e13. PubMed ID: 34224739 [TBL] [Abstract][Full Text] [Related]
3. A Frameshift Peptide Neoantigen-Based Vaccine for Mismatch Repair-Deficient Cancers: A Phase I/IIa Clinical Trial. Kloor M; Reuschenbach M; Pauligk C; Karbach J; Rafiyan MR; Al-Batran SE; Tariverdian M; Jäger E; von Knebel Doeberitz M Clin Cancer Res; 2020 Sep; 26(17):4503-4510. PubMed ID: 32540851 [TBL] [Abstract][Full Text] [Related]
4. Lynch Syndrome and MSI-H Cancers: From Mechanisms to "Off-The-Shelf" Cancer Vaccines. Roudko V; Cimen Bozkus C; Greenbaum B; Lucas A; Samstein R; Bhardwaj N Front Immunol; 2021; 12():757804. PubMed ID: 34630437 [TBL] [Abstract][Full Text] [Related]
5. Serum antibodies against frameshift peptides in microsatellite unstable colorectal cancer patients with Lynch syndrome. Reuschenbach M; Kloor M; Morak M; Wentzensen N; Germann A; Garbe Y; Tariverdian M; Findeisen P; Neumaier M; Holinski-Feder E; von Knebel Doeberitz M Fam Cancer; 2010 Jun; 9(2):173-9. PubMed ID: 19957108 [TBL] [Abstract][Full Text] [Related]
6. Immune response against frameshift-induced neopeptides in HNPCC patients and healthy HNPCC mutation carriers. Schwitalle Y; Kloor M; Eiermann S; Linnebacher M; Kienle P; Knaebel HP; Tariverdian M; Benner A; von Knebel Doeberitz M Gastroenterology; 2008 Apr; 134(4):988-97. PubMed ID: 18395080 [TBL] [Abstract][Full Text] [Related]
7. The Immune Biology of Microsatellite-Unstable Cancer. Kloor M; von Knebel Doeberitz M Trends Cancer; 2016 Mar; 2(3):121-133. PubMed ID: 28741532 [TBL] [Abstract][Full Text] [Related]
9. Clinical significance of microsatellite instability in colorectal cancer. Kloor M; Staffa L; Ahadova A; von Knebel Doeberitz M Langenbecks Arch Surg; 2014 Jan; 399(1):23-31. PubMed ID: 24048684 [TBL] [Abstract][Full Text] [Related]
10. Vaccines for immunoprevention of DNA mismatch repair deficient cancers. Hernandez-Sanchez A; Grossman M; Yeung K; Sei SS; Lipkin S; Kloor M J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35732349 [TBL] [Abstract][Full Text] [Related]
11. Microsatellite instability and DNA mismatch repair protein deficiency in Lynch syndrome colorectal polyps. Yurgelun MB; Goel A; Hornick JL; Sen A; Turgeon DK; Ruffin MT; Marcon NE; Baron JA; Bresalier RS; Syngal S; Brenner DE; Boland CR; Stoffel EM Cancer Prev Res (Phila); 2012 Apr; 5(4):574-82. PubMed ID: 22262812 [TBL] [Abstract][Full Text] [Related]
12. [Pathogenesis of microsatellite-unstable colorectal cancer. Evaluation of new diagnostic and therapeutic options]. Kloor M Pathologe; 2013 Nov; 34 Suppl 2():277-81. PubMed ID: 24196629 [TBL] [Abstract][Full Text] [Related]
13. Lynch syndrome and Lynch syndrome mimics: The growing complex landscape of hereditary colon cancer. Carethers JM; Stoffel EM World J Gastroenterol; 2015 Aug; 21(31):9253-61. PubMed ID: 26309352 [TBL] [Abstract][Full Text] [Related]
14. BRAF V600E-specific immunohistochemistry for the exclusion of Lynch syndrome in MSI-H colorectal cancer. Capper D; Voigt A; Bozukova G; Ahadova A; Kickingereder P; von Deimling A; von Knebel Doeberitz M; Kloor M Int J Cancer; 2013 Oct; 133(7):1624-30. PubMed ID: 23553055 [TBL] [Abstract][Full Text] [Related]
15. Hereditary prostate cancer as a feature of Lynch syndrome. Bauer CM; Ray AM; Halstead-Nussloch BA; Dekker RG; Raymond VM; Gruber SB; Cooney KA Fam Cancer; 2011 Mar; 10(1):37-42. PubMed ID: 20872076 [TBL] [Abstract][Full Text] [Related]
16. A cancer vaccine approach for personalized treatment of Lynch Syndrome. Majumder S; Shah R; Elias J; Manoharan M; Shah P; Kumari A; Chakraborty P; Kode V; Mistry Y; Coral K; Mittal B; Sm SM; Mahadevan L; Gupta R; Chaudhuri A; Khanna-Gupta A Sci Rep; 2018 Aug; 8(1):12122. PubMed ID: 30108227 [TBL] [Abstract][Full Text] [Related]
17. Combined Microsatellite Instability, MLH1 Methylation Analysis, and Immunohistochemistry for Lynch Syndrome Screening in Endometrial Cancers From GOG210: An NRG Oncology and Gynecologic Oncology Group Study. Goodfellow PJ; Billingsley CC; Lankes HA; Ali S; Cohn DE; Broaddus RJ; Ramirez N; Pritchard CC; Hampel H; Chassen AS; Simmons LV; Schmidt AP; Gao F; Brinton LA; Backes F; Landrum LM; Geller MA; DiSilvestro PA; Pearl ML; Lele SB; Powell MA; Zaino RJ; Mutch D J Clin Oncol; 2015 Dec; 33(36):4301-8. PubMed ID: 26552419 [TBL] [Abstract][Full Text] [Related]
18. The Importance of Distinguishing Sporadic Cancers from Those Related to Cancer Predisposing Germline Mutations. Sorscher S Oncologist; 2018 Nov; 23(11):1266-1268. PubMed ID: 29866945 [TBL] [Abstract][Full Text] [Related]
19. Recent discoveries in the molecular genetics of Lynch syndrome. Boland CR Fam Cancer; 2016 Jul; 15(3):395-403. PubMed ID: 27038793 [TBL] [Abstract][Full Text] [Related]